Home LiteratureArticle Details
PMID: 17704824 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

British journal of pharmacology ·Vol. 152 ·No. 5 ·2007-11-00 ·Pages 576-82

O'Sullivan SE

Abstract

Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan receptor and the transmitter-gated channel transient receptor potential vanilloid type-1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator-activated receptors (PPARs, with three subtypes alpha, beta (delta) and gamma), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR alpha. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR alpha. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti-inflammatory properties mediated by PPAR alpha. Other endocannabinoids that activate PPAR alpha include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR gamma; anandamide and 2-arachidonoylglycerol have anti-inflammatory properties mediated by PPAR gamma. Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma. THC also activates PPAR gamma, leading to a time-dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR gamma include N-arachidonoyl-dopamine, HU210, WIN55212-2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPAR delta. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro- and cardioprotective benefits as other PPAR alpha and PPAR gamma agonists? This review will summarize the published literature implicating cannabinoid-mediated PPAR effects and discuss the implications thereof.

MeSH Terms
Animals Cannabinoids/chemistry,metabolism,pharmacology Humans Ligands Models, Biological Molecular Structure Peroxisome Proliferator-Activated Receptors/agonists,metabolism
Chemicals
Cannabinoids Ligands Peroxisome Proliferator-Activated Receptors
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
O'Sullivan S E
School of Biomedical Sciences, University of Notttingham, Queen's Medical Center, Nottingham, UK. saoirse.o'[email protected]
References (42)
42 references, click to expand
  1. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line.
    Int J Cancer. 2003 Mar 10;104(1):12-8 PMID: 12532414
  2. PPAR agonists in the treatment of atherosclerosis.
    Curr Opin Pharmacol. 2003 Apr;3(2):186-91 PMID: 12681242
  3. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.
    J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80 PMID: 16684820
  4. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Anal Biochem. 2005 Sep 1;344(1):8-15 PMID: 16038868
  5. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.
    Eur J Pharmacol. 2007 Jul 2;566(1-3):117-9 PMID: 17434479
  6. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.
    Am J Physiol Cell Physiol. 2005 Apr;288(4):C899-905 PMID: 15590897
  7. Cannabinoids and PPARalpha signalling.
    Biochem Soc Trans. 2006 Dec;34(Pt 6):1095-7 PMID: 17073758
  8. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties.
    J Pharmacol Exp Ther. 2006 Aug;318(2):563-70 PMID: 16702440
  9. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake.
    Cell Mol Life Sci. 2007 Jan;64(2):219-29 PMID: 17187172
  10. Going nuclear in metabolic and cardiovascular disease.
    J Clin Invest. 2006 Mar;116(3):556-60 PMID: 16511587
  11. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Biochim Biophys Acta. 2007 Aug;1771(8):1094-107 PMID: 17459763
  12. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.
    Trends Pharmacol Sci. 2004 Jun;25(6):331-6 PMID: 15165749
  13. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.
    Diabetes. 2004 Feb;53 Suppl 1:S43-50 PMID: 14749265
  14. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.
    Mol Pharmacol. 2003 May;63(5):983-92 PMID: 12695526
  15. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.
    Eur J Pharmacol. 2005 Jul 11;517(3):174-81 PMID: 15987634
  16. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma.
    J Biol Chem. 2007 Jun 22;282(25):18625-33 PMID: 17462987
  17. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2.
    Mol Pharmacol. 2006 Jul;70(1):101-11 PMID: 16611855
  18. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
    J Biol Chem. 2004 Jul 2;279(27):27849-54 PMID: 15123613
  19. Peroxisome proliferator-activated receptors in the cardiovascular system.
    Br J Pharmacol. 2000 Mar;129(5):823-34 PMID: 10696077
  20. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases.
    Cell Mol Life Sci. 2007 Jun;64(11):1403-18 PMID: 17447008
  21. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha.
    Nature. 2003 Sep 4;425(6953):90-3 PMID: 12955147
  22. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist.
    J Biol Chem. 2002 Jun 28;277(26):23278-86 PMID: 11956198
  23. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.
    Neuroscience. 2004;123(1):131-45 PMID: 14667448
  24. PPAR delta: a dagger in the heart of the metabolic syndrome.
    J Clin Invest. 2006 Mar;116(3):590-7 PMID: 16511591
  25. Cannabinoid signalling.
    Life Sci. 2006 Jan 2;78(6):549-63 PMID: 16109430
  26. PPARs, Obesity, and Inflammation.
    PPAR Res. 2007;2007:95974 PMID: 17389767
  27. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol.
    J Pharmacol Exp Ther. 2006 Apr;317(1):428-38 PMID: 16352700
  28. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages.
    Circ Res. 2007 May 25;100(10):1442-51 PMID: 17463321
  29. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma.
    Biochem Biophys Res Commun. 2005 Nov 25;337(3):824-31 PMID: 16213464
  30. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes.
    J Pharmacol Exp Ther. 2004 Nov;311(2):683-90 PMID: 15284281
  31. Rimonabant in obese patients with type 2 diabetes.
    Lancet. 2007 Feb 17;369(9561):555 PMID: 17307094
  32. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
    J Neurochem. 2005 May;93(4):984-91 PMID: 15857401
  33. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms.
    J Biol Chem. 2002 Nov 1;277(44):41925-30 PMID: 12200443
  34. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.
    Expert Opin Investig Drugs. 2005 Jun;14(6):557-68 PMID: 16004588
  35. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.
    Neuroscience. 2005;130(2):325-37 PMID: 15664689
  36. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients.
    Diabetes. 1997 Aug;46(8):1319-27 PMID: 9231657
  37. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.
    Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23 PMID: 9113987
  38. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Neuropharmacology. 2008 Jan;54(1):226-34 PMID: 17467748
  39. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.
    Mol Pharmacol. 2005 Jan;67(1):15-9 PMID: 15465922
  40. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
    J Pharmacol Exp Ther. 2006 Dec;319(3):1051-61 PMID: 16997973
  41. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Curr Opin Pharmacol. 2006 Dec;6(6):606-14 PMID: 16973418
  42. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta.
    Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33 PMID: 17223076
Article Info
Journal
British journal of pharmacology
Abbr.
Br J Pharmacol
ISSN
0007-1188
Published
2007-11-00
Epub
2007-00-20
Pages
576-82
Language
English
Region
England
NLM ID
7502536
PMCID
PMC2190029
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]